A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer

Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC) (Hoosier Cancer Research Network GU12-160).

(2017) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers

(2016) K. N. Chi et al.   ANNALS OF ONCOLOGY

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

(2016) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer

(2013) M. Shiota et al.   CANCER RESEARCH

Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo

(2012) B Gibert et al.   BRITISH JOURNAL OF CANCER

Advanced Clinical States in Prostate Cancer

(2012) Heather H. Cheng et al.   UROLOGIC CLINICS OF NORTH AMERICA

Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27

(2010) Han-Shui Hsu et al.   CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY